Orchestrated Oncology → About Dr. Mark
Cancer can't be cured with a silver bullet.
It's an integrated process that needs an orchestrated solution.
Standard oncology protocols attack the cancer. They are not designed to ask what the cancer is using to survive that attack.
Oncologists are among the most skilled physicians in medicine. They are also asked to manage dozens of cancer types with 15-minute appointments and treatment plans built largely on drugs that could be commercialized. As Mark puts it: "It's rare to find an oncologist who integrates everything they know about science to treat a cancer. It's almost impossible because they're routed into using protocols that identify specific medications to attack specific pathways, but in reality, the cancer makes defenses in many, many pathways."
Most treatment protocols, he observed, are derived from clinical trials designed to show whether a drug, or perhaps two, used by themselves will give sufficient survival to a sufficient number of people without too much damage. "The more I'm interested about cancer," he says, "the more I realize this is totally inadequate."
Mark is a physician with more than 30 years of clinical experience. He knows how the system works from the inside. And when he heard the word cancer in his own chart (twice) he had already spent years understanding what the standard framework was missing. It gave him the intellectual grounding to engage with his diagnosis. But he is direct about what that experience was: "So I've heard cancer in my chart twice now... I was still frightened of the complexity of what I was to deal with, the unknowns."
The right clinical question, the one the standard protocol doesn't ask, is: what is my cancer using to survive this treatment? That question is where the Lorenzato Process begins.
Mark's entry into this kind of research didn't start with his own diagnosis. It started with a friend.
"I was so fortunate to help a friend who developed a rare cancer that there was no standard protocol for. And that left us, a very smart woman and myself, trying to understand how we could use various protocols and repurpose medicines to slow her growth of her cancer and kill her cancer. I was drawn into searching through the literature until I found key studies that showed we could kill her cancer in petri dishes and then look in animals to see what studies were done. And eventually, we came up with a list of six or seven medicines that we could give at the same time we thought would kill her cancer. We were successful. More than 95% of her cancer cells went away with this therapy."
That experience convinced him that silver-bullet therapy was obsolete: the methodology of using targeted, single-mechanism treatment was leaving enormous potential on the table.
He developed a reasoning framework for doing this systematically: the Lorenzato Process. It starts with a question standard protocols don't ask. It maps the specific defenses a patient's cancer is using to survive treatment. It traces those defenses upstream through their metabolic supply chains to find the chokepoints: places where multiple defense pathways converge on the same substrate, and where the right intervention can degrade multiple defenses at once. And it times every intervention to the treatment cycle: degrade defenses before treatment arrives, coordinate with the strike, then manage recovery and prevent reconstitution afterward.
Working through this manually (reading the primary research, tracing the metabolic pathways, evaluating timing and sequencing across treatment cycles) produces results that standard care doesn't reach. But manual work at this depth doesn't scale. Each protocol took weeks.
With capable AI tools now available, co-founder Jake, a systems builder, saw a path to doing this at scale. The team built a pipeline of specialized AI agents that now runs this analysis in 24 to 48 hours, going deeper than any individual physician could working manually: tracing supply chains, running adversarial review, computing quantitative kinetic predictions, identifying compensatory bypass pathways that would let the cancer survive even a well-designed attack on its primary defenses.
The team is Dr. Mark (clinical methodology and physician review), Jake (systems and pipeline), and Avery (strategy and product). The system is the product of all three.
Mark is not a board-certified oncologist. He is an emergency and clinic physician who went deep on metabolic oncology because the research demanded it and because what he found was too important to leave as a personal protocol.
That background is relevant context. It means he comes to this work with clinical training and a physician's responsibility to patients, without the pharmaceutical industry relationships that shape much of standard oncology practice. He reviews every protocol this system generates. His name is on every output.
Mark started building protocols for patients: people he knew personally, who asked him for help after their own oncologists had nothing more to offer.
Case A: Rare metastatic thymoma
This patient was trained in risk-benefit analysis. She had been evaluated at Stanford, MD Anderson, Moffitt, Chicago hospitals, and NIH. None of them had additional options for her cancer type. What she valued was not credentials. It was a physician's willingness to engage: to spend more than 15 minutes, to map her cancer's specific defense network, to build something no institution had offered her. Outcome: 95% tumor reduction. She died years later from complications of chemotherapy. Not from the cancer.
Case B: Terminal prognosis, 1 year to live
This patient was given 12 months. He started reading the studies behind the first recommendations, and became committed. He followed the protocol through multiple treatment cycles. Outcome: He survived 3 years. He died of COVID, not cancer.
Case C: Metastatic prostate cancer
Ongoing protocol. Most recent assessment: low-or-no detectable cancer. This case is still in progress.
These outcomes are not presented as guarantees. Cancer is complex. Every case is different. Some patients don't respond. Some respond and then relapse. They are presented because they are real, documented, and demonstrate what the methodology can produce when it works.
The Research Engine
The Lorenzato Process is now implemented as a multi-agent AI pipeline. Understanding how it works matters: both for evaluating what you receive and for understanding why the analysis can reach places manual review cannot.
Specialized agents, not a single AI. Each agent in the pipeline handles a specific analytical domain: defense network mapping, metabolic supply chain tracing, drug interaction analysis, pharmacokinetic modeling, timing and sequencing, safety screening. No single agent handles everything. Specialization is how the system maintains depth across the full complexity of a cancer case.
Adversarial review at every stage. The pipeline includes a Cancer Board stage where multiple specialist agents independently evaluate the protocol, then cross-examine each other's conclusions. Their job is to find flaws: gaps in the defense network mapping, compensatory bypass pathways that were missed, interventions that fail pharmacokinetic gates. Findings that survive this adversarial process are more reliable than findings that were never challenged.
Every claim is supported by peer-reviewed literature. The research agents access PubMed directly and cite every factual claim with a hyperlinked reference. The oncologist reviewing the protocol can verify any claim in 30 seconds. We do not ask anyone to take our conclusions on faith.
Hard gating prevents AI hallucination. Between the research phases and the kinetic modeling phase, an independent LP Audit agent runs a structured compliance check against the biological principles that govern the methodology. It cannot be overridden by the research agents. Verdicts are pass, revision required, or blocking fail. If a protocol fails the audit, it goes back for revision before proceeding.
Full analyses take 24 to 48 hours. This is not a fast lookup. The pipeline runs through a complete causal chain: defense network, metabolic supply chains, compensatory bypasses, drug interactions, kinetic predictions, adversarial review. That depth requires time.
The system quantifies uncertainty explicitly. Every quantitative claim in the output carries an evidence tier (published data, inferred from mechanism, assumed), an uncertainty range, and a source. When the evidence is speculative, the protocol says so. When the combination proposed has never been tested in humans, the protocol says so, including the exact phrase "number of humans who have received this combination: 0" where applicable.
Knowledge accumulates across every analysis. Failed pharmacokinetic gates from previous analyses prevent the system from re-evaluating the same dead ends. Validated mechanisms increase confidence scores in subsequent runs. Clinical corrections from physician review feed back into the knowledge base. The system that runs your analysis has learned from every analysis before it.
Mark reviews, modifies, and signs every output. The AI generates. The physician reviews. No protocol reaches a patient without physician sign-off. We are in conversations with additional oncologists to build a formal physician board review process, with multiple independent physicians verifying each protocol before delivery. That is where we are headed.
This is the starting point, not the finished product. We are currently focused on ferroptosis pathways, with the framework in place to add autophagy, apoptosis, pyroptosis, and other cell death pathways. Transcriptomics integration and more sophisticated drug timing models are in development. The science and the pipeline are improving with every run.
Dr. Mark [Last Name], MD
- Licensed physician, 30+ years of clinical practice
- Licensed to prescribe in California
- Developer of the Lorenzato Process for cancer treatment optimization
- Reviewing physician for all Orchestrated Oncology protocols: every protocol generated by the LP research engine passes through physician review before delivery
What we don't do
We don't sell supplements.
We don't own a pharmacy. We don't have equity in any supplement company.
We have zero affiliate relationships with any drug manufacturer, supplement company, or pharmacy.
We don't earn a commission, referral fee, or kickback from any substance we recommend in a protocol.
Revenue comes from the Protocol Report and the service. Never from the substances in the protocol.
In Mark's words: "We are not beholden to any pharmaceutical company. We create protocols. We create recommendations for protocols that you take to your oncologist. And with those protocols, we feel you can optimize your survival and minimize your collateral damage. We want your doctors to scrutinize us."
In a space where most providers have financial ties to the products they recommend: our only incentive is to give your loved one the best protocol we can build.
Not every patient responds. Not every cancer can be optimized. The biology is complex, the evidence is still evolving, and there are cases where even the most rigorous protocol cannot change the trajectory.
Mark is direct about this: "There is always a chance of dying, from complications or from the cancer itself. What we can do is just minimize those risks. That's what we work towards."
And when there is nothing more to optimize, we say so. "We're in it to make the cancer easier to manage and for you to survive the longest you can."
That commitment, to be relentlessly thorough and relentlessly honest, is why Orchestrated Oncology exists. For families who are searching at midnight, coordinating care across time zones, and trying to find something their oncologist will take seriously.
A note for treating oncologists
If your oncologist wants to know who we are and how to evaluate the protocol, this section is for them.
If a patient or family member has brought you an Orchestrated Oncology Protocol Report, we welcome your evaluation.
Every recommendation in the protocol cites a peer-reviewed study. PubMed IDs are included so you can verify any claim in 30 seconds. The protocol is designed to complement your treatment plan, not replace it.
We are not asking you to adopt our recommendations. We are asking you to evaluate them with the same clinical rigor you bring to any proposed intervention. If you have questions, concerns, or want to discuss the case, you can reach Dr. Mark directly at [contact email/phone].
This was built because families deserve more than 15 minutes. Your expertise is the foundation their treatment stands on. Our role is to address the metabolic layer that your appointment doesn't have time for.